Form 4: Equillium COO Exercises Options, Sells Shares

Equillium's Senior Vice President and COO, Christine Zedelmayer, exercised stock options and subsequently sold 100,000 shares of common stock.

Summary

• Christine Zedelmayer, Senior Vice President and Chief Operating Officer of Equillium, Inc., reported transactions on December 23, 2025.
• Exercised employee stock options to acquire 100,000 shares of common stock at an exercise price of $0.785 per share.
• Immediately after the exercise, sold 100,000 shares of common stock at a price of $1.50 per share.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 27, 2025.
• Following these transactions, Christine Zedelmayer beneficially owns 91,444 shares of Equillium common stock directly.
• The exercised options had an expiration date of January 3, 2031, and a vesting schedule where 25% vested on the first anniversary of the commencement date, with the remainder vesting in 36 equal monthly installments thereafter for the following three years.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction (exercise and sell-to-cover or pre-planned sale) which is common for executives managing their equity compensation. It doesn't inherently signal strong positive or negative sentiment about the company's future, especially given the 10b5-1 plan.

Positives

• The exercise of options indicates a prior grant of equity compensation to a key executive.
• The sale price of $1.50 per share is higher than the exercise price of $0.785, indicating a profit for the executive.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, potentially raising questions about management's confidence.

Risks

• No specific risks related to company operations or future outlook are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This filing details an individual insider transaction and does not contain information suitable for comparison to global industry benchmarks or specific comparable companies/projects.

Related Party Transactions

• The reported transactions are between an executive and the company's stock, which is a common form of equity compensation and subsequent sale, not typically classified as an unusual related-party transaction in this context beyond the executive's relationship.

Stakeholder Impact

• The sale of shares by a Senior Vice President and COO could be interpreted by some shareholders as a lack of confidence, though the existence of a Rule 10b5-1 plan suggests a pre-scheduled transaction rather than a reaction to new information. There is no direct impact on employees, customers, suppliers, or creditors mentioned.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and a subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are common for executives managing their personal finances and equity compensation and do not typically provide new fundamental information about the company's operational performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Equillium, EQ, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Christine Zedelmayer, 10b5-1 Plan, Corporate Officer